Evidence map›Paper›PMID 39828218›Full record

Trial reportJournal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer2025

A Single-Arm Phase 2 Study of Sotorasib Plus Carboplatin and Pemetrexed in Patients With Advanced Nonsquamous NSCLC With KRAS G12C Mutation (WJOG14821L, SCARLET).

Hiroaki Akamatsu, Shinya Sakata, Koichi Azuma, Hiroshige Yoshioka, Takehiro Uemura, Yuko Tsuchiya-Kawano, Seiya Esumi, Takashi Kurosaki, Yuki Sato, Tomohiro Sakamoto and 13 more

Abstract readClinical Trial, Phase II
PubMed Publisher
In one paragraph

Trial report in Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Review
  6. Chemotherapy in combination with KRAS inhibitors inJournal of thoracic disease · 2026
    Article
  7. Article
  8. Article
  9. Article
  10. [Advances in Diagnosis and Targeted Therapy of KRASG12C Mutant 
Non-small Cell Lung Cancer].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2025
    Review
  11. ATR expression as a prognostic biomarker inJournal of thoracic disease · 2025
    Article
  12. Review
  13. Article
  14. Review
  15. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

23 authors.

Hiroaki AkamatsuInternal Medicine III, Wakayama Medical University, Wakayama, Japan. Electronic address: hiroakiakamatsu@gmail.com.
Shinya SakataDepartment of Respiratory Medicine, Kumamoto University Hospital, Kumamoto, Japan.
Koichi AzumaDivision of Respirology, Neurology, and Rheumatology, Department of Internal Medicine, Kurume University School of Medicine, Kurume, Fukuoka, Japan.
Hiroshige YoshiokaDepartment of Thoracic Oncology, Kansai Medical University, Hirakata, Osaka, Japan.
Takehiro UemuraDepartment of Respiratory Medicine, Allergy and Clinical Immunology, Nagoya City University Graduate School of Medical Sciences, Nagoya, Aichi, Japan.
Yuko Tsuchiya-KawanoDepartment of Respiratory Medicine, Kitakyushu Municipal Medical Center, Kita-kyushu, Fukuoka, Japan.
Seiya EsumiRespiratory Center, Matsusaka Municipal Hospital, Matsusaka, Mie, Japan.
Takashi KurosakiDepartment of Medical Oncology, Kindai University Faculty of Medicine, Osakasayama, Osaka, Japan.
Yuki SatoDepartment of Respiratory Medicine, Kobe City Medical Center General Hospital, Kobe, Japan.
Tomohiro SakamotoDivision of Respiratory Medicine and Rheumatology, Department of Multidisciplinary Internal Medicine, Faculty of Medicine, Tottori University, Yonago, Tottori, Japan.
Kiichiro NinomiyaCenter for Comprehensive Genomic Medicine, Okayama University Hospital, Okayama, Japan.
Ryo ToyozawaDepartment of Thoracic Oncology, NHO Kyushu Cancer Center, Fukuoka, Japan.
Yasuto YoneshimaDepartment of Respiratory Medicine, Graduate School of Medical Sciences, Kyushu University, Hakata, Fukuoka, Japan.
Takehito ShukuyaDepartment of Respiratory Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan.
Toshiyuki KozukiDepartment of Thoracic Oncology and Medicine, NHO Shikoku Cancer Center, Matsuyama, Ehime, Japan.
Kana WatanabeDepartment of Respiratory Medicine, Miyagi Cancer Center, Sendai, Miyagi, Japan.
Haruko DagaDepartment of Medical Oncology, Osaka City General Hospital, Osaka, Japan.
Terufumi KatoDepartment of Thoracic Oncology, Kanagawa Cancer Center, Yokohama, Kanagawa, Japan.
Toshiaki TakahashiDivision of Thoracic Oncology, Shizuoka Cancer Center, Sunto-Gun, Shizuoka, Japan.
Mitsuo OsugaCenter for Biomedical Sciences, Wakayama Medical University, Wakayama, Japan.
Yasuhiro KohInternal Medicine III, Wakayama Medical University, Wakayama, Japan; Center for Biomedical Sciences, Wakayama Medical University, Wakayama, Japan.
Satoshi MoritaDepartment of Biomedical Statistics and Bioinformatics, Kyoto University Graduate School of Medicine, Kyoto, Japan.
Nobuyuki YamamotoInternal Medicine III, Wakayama Medical University, Wakayama, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThe efficacy and safety of sotorasib plus platinum doublet chemotherapy in KRAS G12C-mutated nonsquamous NSCLC (nonsq NSCLC) have been previously reported with a limited follow-up period.

methodsSCARLET is a single-arm phase 2 study involving chemotherapy-naive patients with KRAS G12C-mutated nonsq NSCLC. The participants received 960 mg daily plus four cycles of carboplatin (area under the curve = 5)/pemetrexed 500 mg/m

resultsThirty patients were enrolled between October 2021 and July 2022 with a median follow-up of 14.8 months. ORR was 88.9% (80% confidence interval [CI]: 78.5%-94.8%, 95% CI: 70.8%-97.6%), median PFS was 6.6 months (95% CI: 5.3-16.7 mo), and median overall survival was 20.6 months (95% CI: 8.1 mo-not estimated). Among patients with programmed death-ligand 1 expression levels of 1% or higher and less than 1%, the ORRs were 82.3 and 100%, respectively, and the median PFS was 7.6 and 9.7 months, respectively. Using plasma samples, patients without KRAS G12C at baseline, without KRAS-related pathway co-alterations, or who cleared KRAS G12C at 3 weeks had better median PFS (16.7, 13.9, 8.7 mo, respectively). Tumor protein 53 mutations and EGFR and MET amplification were detected as acquired resistance.

conclusionsIn patients with KRAS G12C-mutated nonsq NSCLC, sotorasib plus carboplatin/pemetrexed reported favorable efficacy, particularly for patients with less than 1% programmed death-ligand 1, with manageable toxicity.

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsCarcinoma, Non-Small-Cell LungLung NeoplasmsProto-Oncogene Proteins p21(ras)SulfonamidesAdultAgedCarboplatinFemaleHumansMaleMiddle AgedMutationPemetrexedPiperazinesPyridinesCarboplatinKRAS protein, humanPemetrexedPiperazinesProto-Oncogene Proteins p21(ras)PyridinesPyrimidinessotorasibSulfonamidesKRAS G12CNonsquamous non–small cell lung cancerSotorasib

Identifiers

PMID39828218

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.